Mental dysfunction in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 4, Issue 3, 1998, Pages 107-112

  Wolters, E Ch ^a   Francot, C M J E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Cognition; Depression; Mental dysfunction; Parkinson's disease; Psychosis

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

AFFECTIVE NEUROSIS; ARTICLE; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; HUMAN; LIMBIC CORTEX; MENTAL DISEASE; MOTOR DYSFUNCTION; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM;

EID: 0032423103     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(98)00022-4     Document Type: Article

References (38)

1. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci, 1986;9:357-381.
2. Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol, 1993;50:873-880.
3. Groenewegen HJ, Cortical-subcortical relationships and the limbic forebrain. In: Timble MR, Cummings JL, editors. Contemporary behavioral neurology. Boston, MA: Butterworth-Heinemann, 1997:29-48.
4. Graybiel AM. The basal ganglia and cognitive pattern generators. Schizophren Bull, 1997;23:459-469.
5. Cools AR, Berger HJC, Buytenhuis EL, Horstink MWIM, Van Spaendonck KPM. Manifestations of switching disorders in animal and man with dopamine deficits in A10 and/or A9 circuitries. In: Wolters ECh, Scheltens Ph, editors. Mental dysfunction in Parkinson's disease. Current issues in neurodegenerative diseases, vol. 1. Dordrecht: ICG publications, 1994:49-67.
6. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol, 1997;244:2-8.
7. Owen AM, Robbins TW. Comparative neuropsychology of parkinsonian syndromes. In: Wolters ECh, Scheltens Ph, editors. Mental dysfunction in Parkinson's disease. Current issues in neurodegenerative diseases, vol. 1. Dordrecht: ICG publications, 1994:221-242.
8. Milner B. Effects of different brain lesions on card-sorting: the role of the frontal lobes. Arch Neurol, 1963;9:90-100.
9. Nelson HE. A modified card sorting test sensitive to frontal lobe defects. Cortex, 1976;12:313-324.
10. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain, 1988;111:323-345.
11. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease: the cortical focus of neostriatal outflow. Brain, 1986;109:845-883.
12. Gabrieli JDE, Singh J, Stebbins GT, Goetz CG. Reduced working memory span in Parkinson's disease: evidence for the role of a frontostriatal system in working and strategic memory. Neuropsychology, 1996;10:322-332.
13. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain, 1991;114:2095-2122.
14. Brown LL, Schneider JS, Lidsky TI. Sensory and cognitive functions of the basal ganglia. Curr Opin Neurobiol, 1997;7:157-163.
15. Brown RG, Marsden CD. How common is dementia in Parkinson's disease?. Lancet, 1984;1:1262-1265.
16. Jellinger KA, Bancher Ch, Fischer P. Neuropathological correlates of mental dysfunction in Parkinson's disease. In: Wolters ECh, Scheltens Ph, editors. Mental dysfunction in Parkinson's disease. Current issues in neurodegenerative diseases, vol. 1. Dordrecht: ICG publications, 1994:141-161.
17. Lieberman AN. Point of view: dementia in Parkinson's disease. Parkinsonism and related disorders, 1997;3:151-158.
18. Jacobs DM, Marder K, Coté LJ, Sano M, Stern Y, Mayeux R. Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology, 1995;45:1691-1696.
19. Piccirilli M, D'Alessandro P, Finali G, Piccinin G. Early frontal impairment as a predictor of dementia in Parkinson's disease [letter]. Neurology, 1997;48:546-547.
20. Klein C, Kömpf D, Pulkowski U, Moser A, Vieregge P. A study of visual hallucinations in patients with Parkinson's disease. J Neurol, 1997;244:371-377.
21. Kuzis G, Sabe L, Tiberti C, Leiguarda R, Starkstein SE. Cognitive functions of major depression and Parkinson's disease. Arch Neurol, 1997;54:982-986.
22. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry, 1992;149:443-454.
23. Brown RG, MacCarthy B. Psychiatric morbidity in patients with Parkinson's disease. Psychol Medicine, 1990;20:77-87.
24. Hoogendijk WJG, Sommer IEC, Tissingh G, Deeg DJH, Wolters ECh. Depression in Parkinson's disease: the impact of symptom overlap on prevalence. Psychosomatics, in press.
25. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. Arch Neurol, 1996;53:175-179.
26. Huber SJ, Freidenberg DL, Paulson GW, Shuttleworth EC, Christy JA. The pattern of depressive symptoms varies with progression of Parkinson's disease. J Neurol Neurosurg Psychiatry, 1990;53:275-278.
27. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol, 1990;2:3-9.
28. Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG. Depression in Parkinson's disease. J Nerv Ment Dis, 1990;178:27-31.
29. Van Praag HM. Serotonin and affective psychopathology in Parkinson's disease. A psychobiological hypothesis with therapeutic consequences. In: Wolters ECh, Scheltens Ph, editors. Mental dysfunction in Parkinson's disease. Current issues in neurodegenerative diseases, vol. 1. Dordrecht: ICG publications, 1994:335-348.
30. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak SJ, Dolan RJ. Depression in Parkinson's disease: a positron emission study. BrJ Psychiatry, 1994;165:333-339.
31. Damasio AR. Towards a neuropathology of emotion and mood. Nature, 1997;386:769-770.
32. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc, 1991;39:708-716.
33. Auzou P, Ozsancak C, Hannequin D, Moore N, Augustin P. Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol Scand, 1996;94:329-336.
34. Sandor P, Lang A, Singal S, Angus C. Remoxipride in the treatment of levodopa-induced psychosis. J Clin Psychopharmacology, 1996;16:395-399.
35. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SA, Beasley C et al.. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacology, 1997;17:407-418.
36. Wolters ECh, Jansen ENH, Bergmans PML, Tuynman-Qua HG. Olanzapine in the treatment of dopaminometic psychosis. Neurology, 1996;47:1085-1087.
37. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacology, 1995;15(S1):11-18.
38. Cummings JL. Psychosis in basal ganglia disorders. In: Wolters ECh, Scheltens Ph, editors. Mental dysfunction in Parkinson's disease. Current issues in neurodegenerative diseases, vol. 1. Dordrecht: ICG publications, 1994:257-268.